{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:37:31Z","timestamp":1780504651033,"version":"3.54.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31870809"],"award-info":[{"award-number":["31870809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Sorafenib (SOR) is an oral, potent, selective, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used as the first-line therapy for advanced hepatocellular carcinoma (HCC). Baicalin (BG) is used as adjuvant therapy for hepatitis, which accounts for the leading cause of the development of HCC, and is commonly coadministered with SOR in clinic. The purpose of the current study was to characterize the pharmacokinetic changes of SOR and the potential mechanism when SOR is administered concomitantly with BG in rats for single and multiple doses.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Parallel randomized pharmacokinetic studies were performed in rats which received SOR (50\u00a0mg\/kg, <jats:italic>i.g.<\/jats:italic>) alone or coadministered with BG (160\u00a0mg\/kg, <jats:italic>i.g.<\/jats:italic>) for single and multiple doses (7\u00a0days). Plasma SOR levels were quantified by ultra-performance liquid chromatography\u2013tandem mass spectrometry (UPLC-MS\/MS). Rat liver microsomes (RLMs) which isolated from their livers were analyzed for CYP3A and SOR metabolism activities. The inhibitory effect of BG on the metabolism of SOR was also assessed in pooled human liver microsomes (HLMs). The effects of BG on the intestine absorption behaviors of SOR were assessed in the <jats:italic>in situ<\/jats:italic> single-pass rat intestinal perfusion model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Coadministration with BG (160\u00a0mg\/kg, <jats:italic>i.g.<\/jats:italic>) for single or multiple doses significantly increased the C<jats:sub>max<\/jats:sub>, AUC<jats:sub>0\u2013t<\/jats:sub>, and AUC<jats:sub>0\u2013\u221e<\/jats:sub> of orally administered SOR by 1.68-, 1.73-, 1.70-fold and 2.02-, 1.65-, 1.66- fold in male rats and by 1.85-, 1.68-, 1.68-fold and 1.57-, 1.25-, 1.24- fold in female rats, respectively (<jats:italic>p<\/jats:italic> &amp;lt; 0.01 or <jats:italic>p<\/jats:italic> &amp;lt; 0.05). <jats:italic>In vitro<\/jats:italic> incubation assays demonstrated that there were no significant differences of <jats:italic>K<\/jats:italic><jats:sub><jats:italic>m<\/jats:italic><\/jats:sub>, <jats:italic>V<\/jats:italic><jats:sub><jats:italic>max<\/jats:italic><\/jats:sub>, and <jats:italic>CL<\/jats:italic><jats:sub><jats:italic>int<\/jats:italic><\/jats:sub> of 1-OH MDZ and SOR N-oxide in RLMs between control and multiple doses of BG-treated groups. BG has no obvious inhibitory effects on the metabolism of SOR in HLMs. In comparison with SOR alone, combining with BG significantly increased the permeability coefficient (<jats:italic>P<\/jats:italic><jats:sub><jats:italic>eff<\/jats:italic><\/jats:sub>) and absorption rate constant (<jats:italic>K<\/jats:italic><jats:sub><jats:italic>a<\/jats:italic><\/jats:sub>) of the SOR <jats:italic>in situ<\/jats:italic> single-pass rat intestinal perfusion model.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Notably enhanced oral bioavailability of SOR by combination with BG in rats may mainly account for BG-induced SOR absorption. A greater understanding of potential DDIs between BG and SOR in rats makes major contributions to clinical rational multidrug therapy in HCC patients. Clinical trials in humans and HCC patients need to be further confirmed in the subsequent study.<\/jats:p>","DOI":"10.3389\/fphar.2021.761763","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T07:07:14Z","timestamp":1636355234000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption"],"prefix":"10.3389","volume":"12","author":[{"given":"Jingyao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaibing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1021\/mp200465c","article-title":"Insight into the Cooperation of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood-Brain Barrier: a Case Study Examining Sorafenib Efflux Clearance","volume":"9","author":"Agarwal","year":"2012","journal-title":"Mol. Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpba.2017.04.053","article-title":"Simultaneous Analysis of Regorafenib and Sorafenib and Three of Their Metabolites in Human Plasma Using LC-MS\/MS","volume":"142","author":"Allard","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/17425255.2013.802772","article-title":"Experimental Models for Predicting Drug Absorption and Metabolism","volume":"9","author":"Alqahtani","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejca.2011.12.026","article-title":"Phase I Trial to Investigate the Safety, Pharmacokinetics and Efficacy of Sorafenib Combined with Docetaxel in Patients with Advanced Refractory Solid Tumours","volume":"48","author":"Awada","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejps.2018.02.004","article-title":"Effect of 5,7-dimethoxyflavone on Bcrp1-Mediated Transport of Sorafenib In Vitro and In Vivo in Mice","volume":"117","author":"Bae","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1002\/ptr.7046","article-title":"Promising Influences of Scutellaria Baicalensis and its Two Active Constituents, Baicalin, and Baicalein, against Metabolic Syndrome: A Review","volume":"35","author":"Baradaran Rahimi","year":"2021","journal-title":"Phytotherapy Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1096\/fj.14-269043","article-title":"Translating Dosages from Animal Models to Human Clinical Trials-Rrevisiting Body Surface Area Scaling","volume":"29","author":"Blanchard","year":"2015","journal-title":"FASEB J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2174\/1570179416666190719125730","article-title":"Flavones as a Privileged Scaffold in Drug Discovery: Current Developments","volume":"16","author":"Boniface","year":"2019","journal-title":"Curr. Org. Synth."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1124\/dmd.115.065292","article-title":"The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes","volume":"43","author":"Burns","year":"2015","journal-title":"Drug Metab. Dispos"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e87234","DOI":"10.1371\/journal.pone.0087234","article-title":"Contribution of Baicalin on the Plasma Protein Binding Displacement and CYP3A Activity Inhibition to the Pharmacokinetic Changes of Nifedipine in Rats In Vivo and In Vitro","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejmech.2017.03.004","article-title":"Therapeutic Potentials of Baicalin and its Aglycone, Baicalein against Inflammatory Disorders","volume":"131","author":"Dinda","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-016-3018-6","article-title":"Sorafenib Metabolism, Transport, and Enterohepatic Recycling: Physiologically Based Modeling and Simulation in Mice","volume":"77","author":"Edginton","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B13","first-page":"3546","article-title":"Effects of Baicalin on CYP3A4, CYP2C9 and CYP2C19 Expressions in Chang Liver Cells","volume":"19","author":"Fan","year":"2009","journal-title":"China J. Mod. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/sj.clpt.6100318","article-title":"The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion-Transporting Polypeptide 1B1","volume":"83","author":"Fan","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.2174\/1381612822666160601100823","article-title":"Phytochemicals as Adjunctive with Conventional Anticancer Therapies","volume":"22","author":"Farzaei","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.ctrv.2020.101966","article-title":"Optimizing Treatment of Renal Cell Carcinoma with VEGFR-TKIs: a Comparison of Clinical Pharmacology and Drug-Drug Interactions of Anti-angiogenic Drugs","volume":"84","author":"Fogli","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e89752","DOI":"10.1371\/journal.pone.0089752","article-title":"Inhibition of Baicalin on Metabolism of Phenacetin, a Probe of CYP1A2, in Human Liver Microsomes and in Rats","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e53038","DOI":"10.1371\/journal.pone.0053038","article-title":"Concentration-Dependent Inhibitory Effect of Baicalin on the Plasma Protein Binding and Metabolism of Chlorzoxazone, a CYP2E1 Probe Substrate, in Rats In Vitro and In Vivo","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PharmGKB Summary: Sorafenib Pathways","volume":"27","author":"Gong","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12885-016-2150-3","article-title":"Organic Cation Transporter 1 (OCT1) mRNA Expression in Hepatocellular Carcinoma as a Biomarker for Sorafenib Treatment","volume":"16","author":"Grimm","year":"2016","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"105444","DOI":"10.1016\/j.phrs.2021.105444","article-title":"Baicalin and the Liver-Gut System: Pharmacological Bases Explaining its Therapeutic Effects","volume":"165","author":"Hu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13318-018-0509-3","article-title":"Pharmacokinetics and Bioavailability Enhancement of Baicalin: A Review","volume":"44","author":"Huang","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"113358","DOI":"10.1016\/j.jpba.2020.113358","article-title":"A LC-MS\/MS Method for Therapeutic Drug Monitoring of Sorafenib, Regorafenib and Their Active Metabolites in Patients with Hepatocellular Carcinoma","volume":"187","author":"Iacuzzi","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/ptr.6095","article-title":"Baicalin is a Substrate of OATP2B1 and OATP1B3","volume":"32","author":"Kalapos-Kov\u00e1cs","year":"2018","journal-title":"Phytother Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/ptr.5477","article-title":"Multiple ABC Transporters Efflux Baicalin","volume":"29","author":"Kalapos-Kov\u00e1cs","year":"2015","journal-title":"Phytother Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/pharmaceutics12070600","article-title":"Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats","volume":"12","author":"Karbownik","year":"2020","journal-title":"Pharmaceutics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11095-020-02831-x","article-title":"Investigation of Fluorescent Substrates and Substrate-dependent Interactions of a Drug Transporter Organic Anion Transporting Polypeptide 2B1 (OATP2B1)","volume":"37","author":"Kawasaki","year":"2020","journal-title":"Pharm. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"105824","DOI":"10.1016\/j.intimp.2019.105824","article-title":"Baicalein and Baicalin Promote Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells","volume":"75","author":"Ke","year":"2019","journal-title":"Int. Immunopharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: A Review in Hepatocellular Carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejphar.2010.05.017","article-title":"Induction of CYP3A4 and MDR1 Gene Expression by Baicalin, Baicalein, Chlorogenic Acid, and Ginsenoside Rf through Constitutive Androstane Receptor- and Pregnane X Receptor-Mediated Pathways","volume":"640","author":"Li","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2008.09.005","article-title":"New Therapeutic Aspects of Flavones: the Anticancer Properties of Scutellaria and its Main Active Constituents Wogonin, Baicalein and Baicalin","volume":"35","author":"Li-Weber","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e29282","DOI":"10.1002\/pbc.29282","article-title":"Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors","volume":"68","author":"Meany","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"349531","DOI":"10.1155\/2013\/349531","article-title":"Exploratory Pharmacokinetics of Geniposide in Rat Model of Cerebral Ischemia Orally Administered with or without Baicalin And\/or Berberine","volume":"2013","author":"Pan","year":"2013","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"119836","DOI":"10.1016\/j.ijpharm.2020.119836","article-title":"Preparation and Characterization of Sorafenib-Loaded Microprecipitated Bulk Powder for Enhancing Oral Bioavailability","volume":"589","author":"Park","year":"2020","journal-title":"Int. J. Pharm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchromb.2019.01.003","article-title":"Pharmacokinetic Interaction Study of Novel Combination of Palbociclib and Sorafenib for Hepatocellular Carcinoma in SD Rats","volume":"1108","author":"Paul","year":"2019","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1159\/000497161","article-title":"Sorafenib: Experience and Better Manage-Ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis","volume":"8","author":"Raoul","year":"2019","journal-title":"Liver Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"HEP20","DOI":"10.2217\/hep-2020-0004","article-title":"Systemic Treatment of Hepatocellular Carcinoma: from Sorafenib to Combination Therapies","volume":"7","author":"Roderburg","year":"2020","journal-title":"Hepat. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional Intestinal Permeability in Rats: A Comparison of Methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab. Dispos"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2017.01.038","article-title":"Mathematical Modelling Unveils the Essential Role of Cellular Phosphatases in the Inhibition of RAF-MEK-ERK Signalling by Sorafenib in Hepatocellular Carcinoma Cells","volume":"392","author":"Saidak","year":"2017","journal-title":"Cancer Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"105387","DOI":"10.1016\/j.phrs.2020.105387","article-title":"Baicalin Mediated Regulation of Key Signaling Pathways in Cancer","volume":"164","author":"Singh","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A. Cancer J. Clin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal. Transduct Target. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations","volume":"107","author":"Taskar","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/jphp.13067","article-title":"Baicalin Reduces Ciclosporin Bioavailability by Inducing Intestinal P-Glycoprotein in Rats","volume":"71","author":"Tian","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.cbi.2013.02.005","article-title":"Concentration-dependent Inhibitory Effects of Baicalin on the Metabolism of Dextromethorphan, a Dual Probe of CYP2D and CYP3A, in Rats","volume":"203","author":"Tian","year":"","journal-title":"Chem. Biol. Interact"},{"key":"B47","doi-asserted-by":"publisher","first-page":"179643","DOI":"10.1155\/2013\/179643","article-title":"Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats","volume":"2013","author":"Tian","year":"","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","article-title":"The Drug-Drug Interaction of Sorafenib Mediated by P-Glycoprotein and CYP3A4","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1080\/13880209.2017.1340963","article-title":"The Effects of Triptolide on the Pharmacokinetics of Sorafenib in Rats and its Potential Mechanism","volume":"55","author":"Wang","year":"2017","journal-title":"Pharm. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41419-017-0223-0","article-title":"Baicalin Induces Cellular Senescence in Human colon Cancer Cells via Upregulation of DEPP and the Activation of Ras\/Raf\/MEK\/ERK Signaling","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.ebiom.2019.102610","article-title":"The Microenvironmental and Metabolic Aspects of Sorafenib Resistance in Hepatocellular Carcinoma","volume":"51","author":"Xia","year":"2020","journal-title":"EBioMedicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1002\/jps.23727","article-title":"The Inhibitory Effects of the Bioactive Components Isolated from Scutellaria Baicalensis on the Cellular Uptake Mediated by the Essential Solute Carrier Transporters","volume":"102","author":"Xu","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3389\/fphar.2018.01115","article-title":"Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin through the Inhibition of Efflux Transporters BCRP and MRP2","volume":"9","author":"Xu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/978-981-13-7647-4_8","article-title":"Intestinal Transporter-Associated Drug Absorption and Toxicity","volume":"1141","author":"Xue","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ptr.6033","article-title":"Herb-Drug Interactions in Cancer Care","volume":"32","author":"Yeung","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.12793\/tcp.2020.28.e14","article-title":"Predicting Human Pharmacokinetics from Preclinical Data: Absorption","volume":"28","author":"Yim","year":"2020","journal-title":"Transl Clin. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3892\/or.2017.6153","article-title":"Survival Pathway of Cholangiocarcinoma via AKT\/mTOR Signaling to Escape RAF\/MEK\/ERK Pathway Inhibition by Sorafenib","volume":"39","author":"Yokoi","year":"2018","journal-title":"Oncol. Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.xphs.2015.11.031","article-title":"Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance-Associated Protein 2 and Breast Cancer Resistance Protein","volume":"105","author":"Yu","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"111445","DOI":"10.1016\/j.biopha.2021.111445","article-title":"Drug-herb Interactions between Scutellaria Baicalensis and Pharmaceutical Drugs: Insights from Experimental Studies, Mechanistic Actions to Clinical Applications","volume":"138","author":"Zhou","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.761763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T07:07:19Z","timestamp":1636355239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.761763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":60,"alternative-id":["10.3389\/fphar.2021.761763"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.761763","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"article-number":"761763"}}